Production (Stage)
Addex Therapeutics Ltd
ADXN
$8.40
$0.192.31%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 57.44% | 40.30% | 578.56% | -35.73% | 14.96% |
| Total Depreciation and Amortization | 721.21% | 1,775.76% | 3,666.67% | 6.25% | -95.80% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 11.95% | 88.26% | -2,021.56% | -28.53% | -20.74% |
| Change in Net Operating Assets | -72.07% | 189.01% | -201.66% | 235.57% | 546.55% |
| Cash from Operations | 96.19% | 81.93% | 0.62% | 1.57% | 77.95% |
| Capital Expenditure | 100.00% | -87.50% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -1,192.86% | -750.00% | 184,417.86% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 97.40% | 96.95% | 88.72% | 41.49% | -3.13% |
| Issuance of Common Stock | -90.42% | -- | -99.97% | -79.89% | 57.55% |
| Repurchase of Common Stock | 100.00% | 100.00% | -39.47% | 59.82% | 88.38% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 44.44% | 99.48% | -101.00% | 95.87% | 96.79% |
| Cash from Financing | 96.97% | 99.72% | -101.27% | -83.06% | 62.45% |
| Foreign Exchange rate Adjustments | 116.50% | -228.38% | 101.09% | 461.61% | 0.47% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 99.15% | 81.45% | 36.40% | -73.85% | 72.13% |